ArticleAnnals of medicine and surgery (2012)2025
FDA approval of EBGLYSS™ (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis in adults and children aged 12 and older.
Muhammad Saad Khan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.